Article
FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
2026-02-16
Abstract excerpt
<title>Abstract</title> <p>Background Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited therapeutic options and poor clinical outcomes. While metabolic reprogramming, including altered lipid metabolism, is a recognized hallmark of cancer, its contribution to DMPM progression and treatment response remains poorly understood. Methods Gene expression profiling was pe...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b5f3d671-f0f8-592f-86ff-1e009622b815
- DOI
- 10.21203/rs.3.rs-8641233/v1
